Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK154 +/- AK104/AK112 and mFOLFIRINOX in Resected PDAC
NCT06913218Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK154 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicity and Adverse Events. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
AK154
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06913218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913218.